Business Wire

ADVA

18.2.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA unveils industry’s most compact 100G edge demarcation solution

ADVA (FSE: ADV) today launched the industry’s most compact demarcation and aggregation technology, bringing cost-effective MEF 3.0-certified 100Gbit/s services to the network edge. The ADVA FSP 150-XG400 Series enables businesses and mobile network operators (MNOs) to easily scale their metro networks and tackle booming bandwidth demand. Specifically engineered to deliver MEF 3.0 Carrier Ethernet 100Gbit/s demarcation and 10Gbit/s service aggregation, the new product family features the market’s only uncompromised line-rate 100Gbit/s activation testing. It also supports hardware-based timing for ultra-precise frequency and phase synchronization, making it the ideal choice for radio access networks. With its high-density and environmentally hardened design, the ADVA FSP 150-XG400 Series is also easy to deploy in space-restrictive locations with no temperature control – a key requirement for the rollout of 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005165/en/

“The arrival of 5G is bringing unprecedented data speeds, but mobile applications can only be as fast as the backhaul network. That’s why MNOs are now looking to upgrade their access infrastructure from 10Gbit/s to 100Gbit/s line rates. Our FSP 150-XG400 Series supports a smooth and extremely cost-effective migration to higher capacity while also enabling the distribution of precise network synchronization that next-generation services require,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “With their compact, ETSI-compliant design, our FSP 150-XG400 devices remove the need for deep shelves and excessive rack height units. This makes it easy and affordable to seamlessly upgrade from 1Gbit/s to 10Gbit/s or even 100Gbit/s service delivery. What’s more, the new solutions feature integrated testing capabilities, so operators don’t have to bother with expensive high-bitrate testing equipment.”

The ADVA FSP 150-XG400 Series of high-density service aggregation solutions is the ultimate tool for scaling edge networks for future wholesale, business, mobile fronthaul and backhaul service needs. Available in a 1RU or 2RU form factor, the unprecedentedly compact and highly versatile product range features 1, 10, 25, 40 or 100GbE interfaces. Each device comes with carrier-class Ethernet OAM and Y.1564 feature sets, including unique full line-speed activation testing for services up to 100Gbit/s. The ADVA FSP 150-XG400 Series supports network overlay capabilities for the delivery of MEF services over IP networks. It also provides standard SDN interfaces and can be directly controlled from open source and commercial SDN controllers. Able to withstand an extended temperature range, the ADVA FSP 150-XG400 Series avoids the high cost of air conditioning, enabling ease of deployment even in extreme environments.

“Our newest product family removes all the roadblocks and makes the task of transforming metro networks simple. With our FSP 150-XG400 Series delivering high-density demarcation and aggregation, businesses can expand and embrace the potential of IoT, and operators can deliver the next level of resilient SLA-based Carrier Ethernet services,” commented James Buchanan, GM, Edge Cloud, ADVA. “No other solution available offers such high port count, full testing capabilities and comprehensive network synchronization features with this level of design density. Our devices also provide proven OAM capabilities as well as fully automated service activation. Whether you need high-speed connectivity for cloud-centric business applications or building your enterprise IoT architecture, our FSP 150-XG400 Series has you covered.”

Watch this video for more information on the FSP 150-XG400 Series: https://youtu.be/bCzD9ffS0N8 .

Further details are also available in these slides: https://adva.li/fsp-150-xg400-series-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye